Phase
Condition
Hemophilia
Treatment
Esperoct
Clinical Study ID
Ages > 18 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Signed consent obtained before any study-related activities (study-relatedactivities are any procedure related to recording of data according to theprotocol).
Male, greater than or equal to 18 years of age at the time of signing informedconsent, diagnosed with severe (FVIII activity below 1%) or moderate congenitalhaemophilia A (FVIII activity 1-5%).
The decision to initiate treatment with commercially available Esperoct has beenmade by the patient and the treating physician before and independently from thedecision to include the patient in this study.
Switched, within two months prior to enrolment, OR planned to switch, within onemonth post enrolment, to prophylaxis treatment with Esperoct from previous therapy;the decision to initiate treatment with Esperoct must be made prior to andindependently from the decision to enrol in the study.
Must have baseline data (HJHS, target joints, and medical history) collected inroutine clinical practice within two months prior or up to one month post switch toEsperoct therapy.
Exclusion
Exclusion Criteria:
Previous participation in this study. Participation is defined as having giveninformed consent in this study.
Previous terminated treatment regimen with Esperoct prophylaxis.
Current or previously terminated treatment regimen with Esperoct on-demand.
Mental incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation.
Previous participation in a clinical trial within the 30 days prior to switching toEsperoct.
Study Design
Connect with a study center
Novo Nordisk Investigational Site
Hamilton, Ontario
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.